ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.…
ProQR Announces Third Quarter 2026 Operating and Financial Results
ProQR Therapeutics (NASDAQ: PRQR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 186 employees.
The shares were at 1.040 USD on 20 November 2026, down 51.9% over 52 weeks. Its 52-week range is 1.000 USD to 2.485 USD: the price is 58.1% below the high and 4.0% above the low.
Its market capitalisation is 146.98M USD.
ProQR Therapeutics reports return on equity of -85.4%, an operating margin of -232.6% and revenue up 120.4% year over year.
It holds more cash than debt, a net cash position of 101.81M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 March 2027.